Current Topics in Esophageal Squamous Cell Carcinoma

Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

(2019) Jing Huang et al.   Cancer Communications

OUP accepted manuscript

(2018)   AGE AND AGEING

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

775TiPA phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)

(2018) L Shen et al.   ANNALS OF ONCOLOGY

10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG1000-HCPT conjugate: high stabilizing efficiency and improved antitumor efficacy

(2017) Linjie Yang et al.   International Journal of Nanomedicine

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

(2017) Toshihiro Kudo et al.   LANCET ONCOLOGY

Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer

(2017) Dandan Xu et al.   MEDICINE

Global incidence of oesophageal cancer by histological subtype in 2012

(2014) Melina Arnold et al.   GUT

Drugging Topoisomerases: Lessons and Challenges

(2012) Yves Pommier   ACS Chemical Biology

Long-term Outcome of 2920 Patients With Cancers of the Esophagus and Esophagogastric Junction

(2011) Ralf Gertler et al.   ANNALS OF SURGERY

Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor Growth

(2011) Michael Quante et al.   CANCER CELL

DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition

(2009) Yves Pommier   CHEMICAL REVIEWS